1. Combining glucagon-like peptide 1 receptor agonists and thiazolidinediones in type 2 diabetes patients led to an 80% lower risk of all-cause mortality and major adverse cardiovascular events.
2. The study involved over 220,000 patients in Taiwan and utilized Taiwan's National Health Insurance Research Database for analysis. 
3. Although the benefits of combination therapy were highlighted, caution is advised due to the observational nature of the study.
4. The dual therapy group had a higher risk of hypoglycemia, especially in the first year of use.
5. The lead author, Jing-Xing Li, emphasized the need for further research to confirm long-term safety and determine strategies to manage early hypoglycemia risk.

Source: JAMA Network Open